You are here

580b57fcd9996e24bc43c53e   LinkedIn Logo 500x500   Facebook logo square   Iguana Trans cropped

event icon
Start time
End time
Northern branch

An online talk from Professor Nicola Curtin, Newcastle University, on the development of anti-cancer agent rucaparib

Talk outline

PARP inhibitors (PARPi) represent a paradigm shift in cancer treatment by exploiting tumour-specific defects rather than trying to overcome tumour biology that promote their growth. Initial approvals of PARPi were for ovarian cancer but now include breast, prostate and pancreatic cancer.

In this talk, Professor Nicola Curtin will describe the development of the PARPi, Rubraca®, as well as the part scientists in Newcastle University played, and the collaborations with scientists in academia and the pharmaceutical industry that enabled Rubraca®'s final development to the approval stage.

It is clear that the success of this development was also dependent on several fortuitous events and coincidences of timing, which will also be touched upon in this talk.

Cost and booking

This event is free to attend and open to all. Advance registration is essential through the link at the top of the page.


For specific event queries, please contact the branch chair, Professor Caroline Austin at
For booking or website queries, please contact Harriet McAra at or on 020 3925 3445.